Probiotic preparation capable of relieving allergy and application thereof

Through a combination of probiotic preparations of specific strains and prebiotics, the adverse reactions of anti-allergic drugs in traditional treatment methods are solved, and the symptoms of allergic dermatitis are significantly improved, providing a safe and effective treatment plan.

CN118879527APending Publication Date: 2024-11-01SINOPHARM XINGSHA PHARM XIAMEN CO LTD

Patent Information

Application Number
CN202410827400.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-25
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

Traditional treatment methods for allergic dermatitis have adverse reactions when using anti-allergic drugs for a long time, such as drowsiness, metabolic disorders, and excessive gastric acid secretion, which is especially unfavorable for infants and young children and pregnant women. The prior art is difficult to effectively relieve allergic symptoms.

Method used

Provide a probiotic preparation containing a specific proportion of strains such as Lactobacillus casei, Lactobacillus grenini, Lactobacillus planta, Bifidobacteria longan, Bifidobacteria animal and Lactobacillus reuteri, combined with prebiotics such as xylooligosol , fructose oligosaccharide, used to prepare allergic drugs, significantly improve skin pathological symptoms, reduce serum total IgE levels, regulate inflammatory factors and alleviate mast cell infiltration.

Benefits of technology

It significantly improved the skin pathological symptoms of mice, reduced ear swelling, regulated the level of inflammatory factors and reduced mast cell infiltration, and improved the treatment effect of atopic dermatitis without obvious adverse reactions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118879527A_ABST
    Figure CN118879527A_ABST
Patent Text Reader

Abstract

The invention provides a probiotic agent capable of relieving allergy and application of the probiotic agent. The probiotic agent provided by the invention comprises a lactobacillus casei CCFM1073 strain, a lactobacillus gasseri CCFM1182 strain, a lactobacillus plantarum CCFM1050 strain, a bifidobacterium longum CCFM1029 strain, a bifidobacterium animalis CCFM1155 strain and a lactobacillus reuteri CCFM1145 strain, and has a good effect in the aspects of improving atopic dermatitis and relieving related pathological symptoms. The probiotic agent provided by the invention can be used for preparing drugs for relieving or treating allergy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a probiotic preparation capable of allergy relief and application thereof. Background Art

[0002] Atopic dermatitis (AD) is a chronic, recurrent and inflammatory skin disease with dry skin, recurrent severe itching and eczematoid dermatitis as the main clinical manifestations. AD ranks first in the burden of disease among non-fatal skin diseases. Patients suffer from both physical and psychological torture for a long time, and are unable to study, work and sleep normally. Some patients even suffer from mental disorders such as anxiety, depression and sleep disorders, which seriously affect their quality of life. In recent years, the incidence of allergic diseases has increased year by year worldwide, and it has become a common disease that affects the quality of human life. Traditional prevention methods mainly include: staying away from allergens, strengthening exercise, improving immunity and vaccination. In acute attacks, antiallergic drugs such as glucocorticoids, antihistamines and mast cell membrane stabilizers are mainly used. However, long-term use of antiallergic drugs often leads to adverse reactions, such as drowsiness, metabolic disorders, excessive gastric acid secretion, etc., especially in infants and pregnant women. Summary of the invention

[0003] The purpose of the present invention is to overcome the deficiencies of the prior art, provide a probiotic preparation capable of allergy relief and its application, and solve the problems in the above-mentioned background technology.

[0004] One of the technical solutions adopted by the present invention to solve the technical problem is: provide a probiotic agent capable of allergy relief, characterized in that the probiotic agent capable of allergy relief comprises Lactobacillus casei CCFM1073 strain with a preservation number of GDMCC No: 60736, Lactobacillus gasseri CCFM1182 strain with a preservation number of GDMCC No: 61608, Lactobacillus plantarum CCFM1050 strain with a preservation number of GDMCC No: 60604, Bifidobacterium longum CCFM1029 strain with a preservation number of GDMCC No: 60461, Bifidobacterium animalis CCFM1155 strain with a preservation number of GDMCC No: 61495, Lactobacillus reuteri strain with a preservation number of GDMCC No: 61151, The ratio of the number of viable bacteria of the CCFM1145 strain, the CCFM1073 strain, the CCFM1182 strain, the CCFM1029 strain, the CCFM1050 strain and the CCFM1155 strain is 1:(0.1-10):(0.05-10):(0.1-10):(0.1-10).

[0005] Preferably, in the probiotic agent, the total number of viable bacteria is not less than 1×10 9 CFU / g.

[0006] Preferably, the probiotics further include prebiotics, and the prebiotics contain one or more of xylooligosaccharides, fructooligosaccharides, galacto-oligosaccharides or inulin.

[0007] Preferably, the concentration of the prebiotics is not less than 0.66 g / g.

[0008] Preferably, the probiotics further include food raw materials, and / or food or medically acceptable auxiliary materials or additives.

[0009] Preferably, the dosage form of the probiotic includes lyophilized powder, capsule, tablet or granule.

[0010] The second technical solution adopted by the present invention to solve its technical problem is: to provide the use of the above-mentioned probiotics in the preparation of drugs for alleviating or treating allergies.

[0011] Preferably, the above-mentioned probiotic agent is used in the preparation of a product having at least one of the following functions:

[0012] (1) Can significantly improve the skin pathological symptoms of mice;

[0013] (2) It can significantly improve the swelling of mice's ears;

[0014] (3) It can significantly reduce the total IgE level in mouse serum;

[0015] (4) Can significantly regulate the levels of inflammatory factors in mice;

[0016] (5) It can significantly alleviate mast cell infiltration in the back skin of mice.

[0017] The present invention has the following beneficial effects:

[0018] The present invention designs a probiotic preparation formula for allergy relief based on existing strains. Starting from common respiratory allergies, skin allergies and food allergies, patented strains that have been verified by animal experiments to relieve allergic symptoms in mice, significantly reduce the inflammatory infiltration of mouse mast cells, and regulate the balance of Th1 / Th2 immune responses are added, supplemented with prebiotics that can be used by the strains, and functional dietary raw materials that assist in allergy relief are added. The probiotic preparation of the present invention has the effect of improving atopic dermatitis, which is specifically reflected in:

[0019] 1. Can significantly improve the skin pathological symptoms of mice;

[0020] 2. Can significantly improve the swelling of mice's ears;

[0021] 3. Can significantly reduce the total IgE in mouse serum;

[0022] 4. Can significantly regulate the levels of inflammatory factors in mice;

[0023] 5. It can significantly alleviate mast cell infiltration in the back skin of mice.

[0024] Therefore, the probiotic preparation of the present invention has a good effect in improving atopic dermatitis and alleviating related pathological symptoms. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 Flow chart for modeling animal experiments.

[0026] Figure 2 These are pathological sections of the back skin of experimental mice in different groups.

[0027] Figure 3 The figure shows the degree of ear swelling in different groups of experimental mice.

[0028] Figure 4 This is a graph showing the total serum IgE levels in different groups of experimental mice.

[0029] Figure 5 This is a graph showing the levels of inflammatory factor IL-4 in different groups of experimental mice.

[0030] Figure 6 This is a graph showing the levels of inflammatory factor IL-13 in different groups of experimental mice.

[0031] Figure 7 This is a graph showing the levels of inflammatory factor TSLP in different groups of experimental mice.

[0032] Figure 8 The figure shows the number of mast cells in the back skin of experimental mice in different groups. DETAILED DESCRIPTION

[0033] In order to better understand the present invention, the present invention is further described in detail below in conjunction with the embodiments and drawings. However, those skilled in the art understand that the following embodiments are not limitations on the scope of protection of the present invention, and any changes and modifications made on the basis of the present invention are within the scope of protection of the present invention.

[0034] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0035] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0036] The 2,4-dinitrofluorobenzene (DNFB) involved in the following examples was purchased from Sigma-Aldrich Company, USA; the mouse serum IgE and inflammatory factor detection kits were purchased from R&D Company.

[0037] The deposit information of the deposited strains involved in the following examples is as follows:

[0038] (1) Lactobacillus casei CCFM1073: The deposit number is GDMCC No: 60736, which has been disclosed in patent CN110643541A.

[0039] (2) Lactobacillus gasseri CCFM1182: The deposit number is GDMCC No: 61608, which has been disclosed in patent CN113234644A.

[0040] (3) Lactobacillus plantarum CCFM1050: The deposit number is GDMCC No: 60604, which has been disclosed in patent CN110106122A.

[0041] (4) Bifidobacterium longum CCFM1029: The deposit number is GDMCC No. 60461, which has been disclosed in patent CN109652349A.

[0042] (5) Bifidobacterium animalis CCFM1155: The deposit number is GDMCC No: 61495, which has been disclosed in patent CN113088473A.

[0043] (6) Lactobacillus reuteri CCFM1145: The deposit number is GDMCC No. 61151, which has been disclosed in patent CN112322527A.

[0044] Example 1 Effect of formula intervention on skin pathological symptoms of atopic dermatitis mice The specific steps are as follows:

[0045] 48 SPF female C57BL / 6J mice (6 weeks old, 18-20g) were randomly divided into 6 groups, 8 mice in each group, namely blank group, model group, mixed bacteria group, phytochemical group, old formula group and new formula group. The mice were raised in the Experimental Animal Center of Jiangnan University, with a room temperature of 24℃~26℃, humidity of 40-70%, noise less than or equal to 60dB, animal illumination of 15-20LX, and the experimental animals followed a 12h day and 12h night animal schedule, standard formula commercial feed, free access to food and water. (All animal experimental procedures were reviewed and approved by the Animal Welfare and Ethics Management Committee of Jiangnan University).

[0046] See the modeling process of model animals for details. Figure 1 : The hair on the back of the mice was shaved with a shaver, and a base solution was prepared with acetone and olive oil in a ratio of 4:1. Then, DNFB and the base solution were used to prepare 0.5% and 0.2% DNFB sensitizers. The model was established in the third week. On the first day of modeling, 25 μL of 0.5% DNFB was applied to the back skin and left ear of the mice for sensitization. On the 5th, 8th, 11th, and 14th days, 20 μL of 0.2% DNFB solution was applied to the back skin and left ear of the mice to induce atopic dermatitis. The blank group mice were smeared with the same amount of base solution. When the back skin lesions of the modeling group mice showed severe scabs and fell off, and then turned into scales and scars, and the ears of the modeling group mice gradually hardened and increased in thickness, it proved that the atopic dermatitis model was successfully established.

[0047] The experiment lasted for 28 days: the 1st to 7th day was the adaptation period, and the 8th to 28th day was the gavage intervention. The blank group and the model group were gavaged with 0.2 mL of normal saline; the mixed bacteria group was gavaged with Lactobacillus casei CCFM1073 + Lactobacillus gasseri CCFM1182 + Lactobacillus plantarum CCFM1050 + Bifidobacterium longum CCFM1029 + Bifidobacterium animalis CCFM1155, and the number of live bacteria per gavage reached 1*10 9 CFU, the total number of viable bacteria per day should reach 5*10 9CFU; the phytochemical group was gavaged with xylooligosaccharides + fructooligosaccharides + galacto-oligosaccharides + inulin + green apple powder, and the total daily gavage of phytochemicals reached 0.011g; the old formula group was gavaged with Lactobacillus casei CCFM1073 + Lactobacillus gasseri CCFM1182 + Lactobacillus plantarum CCFM1050 + Bifidobacterium longum CCFM1029 + Lactobacillus reuteri CCFM1145 + xylooligosaccharides + fructo-oligosaccharides + galacto-oligosaccharides + inulin + green apple powder, and the total daily gavage live bacteria count reached 1.43*10 9 CFU, the total daily gavage of plant substances reached 0.011g; the new formula group was gavaged with Lactobacillus casei CCFM1073 + Lactobacillus gasseri CCFM1182 + Lactobacillus plantarum CCFM1050 + Bifidobacterium longum CCFM1029 + Bifidobacterium animalis CCFM1155 + xylooligosaccharides + fructooligosaccharides + galacto-oligosaccharides + inulin + green apple powder, and the total daily gavage live bacteria count reached 1.43*10 9 CFU, the total daily oral administration of plant substances reaches 0.011g. The ratio of Lactobacillus casei CCFM1073, Lactobacillus gasseri CCFM1182, Bifidobacterium longum CCFM1029, Lactobacillus plantarum CCFM1050, and Bifidobacterium animalis CCFM1155 in the composite bacterial agent can be any ratio within the range of 1:(0.1-10):(0.05-10):(0.1-10):(0.1-10).

[0048] DNFB was mixed with a substrate solution (acetone: olive oil = 4:1, v / v) to prepare a sensitizing solution (0.5% and 0.2%). On the 15th day, 0.5% DNFB solution was applied to the shaved back skin and left ear of the mice. Then, 0.2% DNFB solution was applied to the same place, and atopic dermatitis symptoms were induced on days 19, 22, 25 and 28. The blank group mice were smeared with an equal amount of base solution. When the back lesions of the modeling group mice showed severe scabs and fell off, and then turned into scales and scars, and the ears of the modeling group mice gradually hardened and increased in thickness, it proved that the atopic dermatitis model was successfully established.

[0049] See the modeling process of model animals for details. Figure 1 ,The information of animal experiment groups is shown in Table 1.

[0050] Table 1 Animal grouping information

[0051]

[0052] The specific method is as follows:

[0053] Forty-eight SPF female C57BL / 6J mice (6 weeks old, 18-20 g) were randomly divided into 6 groups, 8 mice in each group, namely blank group, model group, mixed bacteria group, phytochemical group, old formula group and new formula group.

[0054] The experimental process is shown in Table 1 and Figure 1 As shown, after the first week of adaptation period;

[0055] Intervention treatment experimental process:

[0056] Blank group: healthy mice without modeling, gavage with normal saline, intervention time (2nd to 3rd week);

[0057] Model group: atopic dermatitis model mice, intragastric administration of normal saline, intervention time (2nd to 3rd week);

[0058] Mixed bacteria group: Atopic dermatitis model mice were gavaged with Lactobacillus casei CCFM1073 + Lactobacillus gasseri CCFM1182 + Lactobacillus plantarum CCFM1050 + Bifidobacterium longum CCFM1029 + Bifidobacterium animalis CCFM1155, and the number of live bacteria per gavage reached 1*10 9 CFU, the total number of viable bacteria per day is 5*10 9 CFU, intervention time (weeks 2–3);

[0059] Phytochemical group: atopic dermatitis model mice, gavage xylooligosaccharide + fructooligosaccharide + galactooligosaccharide + green apple powder + inulin, total gavage phytochemicals per day 0.011g, intervention time (2nd to 3rd week);

[0060] Old formula group: Atopic dermatitis model mice were gavaged with Lactobacillus casei CCFM1073 + Lactobacillus gasseri CCFM1182 + Lactobacillus plantarum CCFM1050 + Bifidobacterium longum CCFM1029 + Lactobacillus reuteri CCFM1145 + xylooligosaccharides + fructo-oligosaccharides + galacto-oligosaccharides + inulin + green apple powder. The total number of viable bacteria per day was 1.43*10 9 CFU, total daily oral administration of phytochemicals reached 0.011 g, intervention time (weeks 2 to 3);

[0061] New formula group: Atopic dermatitis model mice were gavaged with Lactobacillus casei CCFM1073+Lactobacillus gasseri CCFM1182+Lactobacillus plantarum CCFM1050+Bifidobacterium longum CCFM1029+Bifidobacterium animalis CCFM1155+xylooligosaccharides+fructose+galacto-oligosaccharides+green apple powder+inulin. The total number of viable bacteria per day was 1.43*10 9 CFU, total daily oral administration of phytochemicals was 0.011 g, and intervention time (2nd to 3rd week).

[0062] Modeling process: The hair on the back of the mouse was shaved with a shaver, and a base solution was prepared with acetone and olive oil in a ratio of 4:1. Then, DNFB and the base solution were used to prepare 0.5% and 0.2% DNFB sensitizers. Modeling began in the third week. On the first day of modeling, 25 μL of 0.5% DNFB was applied to the back skin and left ear of the mouse for sensitization. On the 5th, 8th, 11th, and 14th days, 20 μL of 0.2% DNFB solution was applied to the back skin and left ear of the mouse to induce atopic dermatitis. The blank group mice were smeared with the same amount of base solution. When the back skin lesions of the modeling group mice showed severe scabs and fell off, and then turned into scales and scars, and the ears of the modeling group mice gradually hardened and increased in thickness, it proved that the atopic dermatitis model was successfully established.

[0063] After the animal experiment, the skin tissue of the mouse modeling site was dissected using 1%-1.5% isoflurane inhalation anesthesia. The skin tissue was fixed with paraformaldehyde, embedded in paraffin, and then cut into 5μm thick slices. Pathological sections were prepared through baking, series of alcohol dehydration, HE staining, decolorization, xylene transparentization, and sealing. The results are shown in Figure 2 .

[0064] The results show that: Figure 2 As shown in the figure, after the modeling, DNFB destroyed the mouse skin barrier, resulting in significant skin lesions on the back skin of the mice. HE section pathological staining showed that the epidermis of the skin tissue of the blank control group was intact, the structure was clear, and the keratinized layer was visible. The collagen fibers in the dermis were neatly arranged, and no inflammatory cell infiltration was observed. The structure of the skin tissue damage in the model group was unclear, the epidermis was missing, a large area of ​​eosinophilic necrosis was visible, the stratum corneum was thickened, a large number of connective tissues, fibroblasts and fibroblasts proliferated, and there were more necrotic fragments, lymphocytes and granulocytes infiltrated. After intervention with plant chemicals, mixed bacteria, and formula products, the pathological symptoms of atopic dermatitis mice were improved to varying degrees, and the skin thickness of mice in the new formula group was significantly reduced and the infiltration of inflammatory cells was significantly improved.

[0065] Example 2 Effect of formula intervention on ear swelling in mice with atopic dermatitis

[0066] The specific steps are as follows: After the mice were killed, specially trained personnel used an electronic vernier caliper to measure the thickness of the middle part of the mouse's left ear and recorded the results. Figure 3 .

[0067] The results show that: Figure 3As shown, the blank group was 0.155±0.012mm, the model group was 0.305±0.05mm, the plant group was 0.249±0.024mm, the mixed bacteria group was 0.254±0.024mm, the old formula group was 0.226±0.021mm, and the new formula group was 0.178±0.033mm. Compared with the blank group, DNFB significantly induced an increase in the thickness of the mice's ears (P<0.001), while the mice in the mixed bacteria group, plant group, and formula group had significantly reduced ear swelling after intervention compared with the model group, and the reduction in ear thickness in the new formula group was greater than that in the other intervention groups (P<0.001).

[0068] Example 3 Effect of formula intervention on total IgE in mouse serum

[0069] The specific steps are as follows: After the animal experiment, 1%-1.5% isoflurane inhalation anesthesia was used to collect blood from the mouse eyeballs. After the serum was separated, the total IgE level of the mouse serum was determined according to the kit instructions. The standard curve was obtained by the external standard method, and the concentration of the substance to be tested in the sample was calculated according to the absorbance. The results are shown in Figure 4 .

[0070] The results show that: Figure 4 As shown, the IgE level of the blank group was 54673.44±10723.48ng / ml, the model group was 117479.55±11415.25ng / ml, the plant group was 84662.05±10381.05ng / ml, the mixed bacteria group was 107861.83±9589.89ng / ml, the old formula group was 82289.04±12033.75ng / ml, and the new formula group was 58801.69±11891.35ng / ml. Compared with 54673.44±21415.31ng / ml in the blank group, the IgE level of mice in the model group increased significantly to 117479.55±11415.25ng / ml (P<0.001). Compared with the model group, phytochemicals, mixed bacteria and formula interventions can all reduce the IgE level in mouse serum. Among them, the new formula group has the best effect in reducing the IgE level in serum and can significantly reduce the expression of IgE in mouse serum (p<0.001).

[0071] Example 4 Effect of formula intervention on inflammatory factors in mice

[0072] The specific steps are as follows: After the animal experiment, the mice were anesthetized with 1%-1.5% isoflurane, the skin tissue was dissected, weighed and counted, and then homogenized with pre-cooled RIPA lysis buffer and protease inhibitor mixture, centrifuged at 11300r / min for 15min at 4℃, and then the supernatant was used to determine the content of IL-4, IL-13 and TSLP in the tissue according to the instructions of the kit. The results are shown in Figure 5 to Figure 7 .

[0073] The results show that: Figure 5 The IL-4 level in the blank group was 1.02±0.75pg / mg protein, the model group was 3.75±1.11pg / mg protein, the plant group was 2.61±0.42pg / mg protein, the mixed bacteria group was 2.92±0.53pg / mg protein, the old formula group was 2.44±0.32pg / mg protein, and the new formula group was 2.18±0.45pg / mg protein. Compared with 1.56±0.23pg / mg protein in the blank group, the IL-4 level in the model group increased significantly to 3.92±0.97pg / mg protein (P<0.01). Compared with the model group, plant, mixed bacteria and formula intervention can reduce the IL-4 level in mouse serum, among which the new formula group has a more significant effect in reducing the IL-4 level in mice (p<0.05), which is better than the plant group, mixed bacteria group and old formula group.

[0074] like Figure 6 As shown, the IL-13 level in the blank group was 124±5.40pg / mg protein, the model group was 162.77±9.80pg / mg protein, the phytochemical group was 144.89±26.94pg / mg protein, the mixed bacteria group was 159.33±23.33pg / mg protein, the old formula group was 136.50±4.12pg / mg protein, and the new formula group was 130.06±3.70pg / mg protein. Compared with the blank group (124±5.40pg / mg protein), the IL-13 level in the model group mice increased significantly to 162.77±9.80pg / mg protein (P<0.01). Compared with the model group, phytochemicals, mixed bacteria and formula interventions can all reduce the IL-13 level in mouse serum. Among them, the new formula group was more effective in reducing the IL-13 level in mice (p<0.05), which was superior to the phytochemical group, mixed bacteria group and old formula group.

[0075] like Figure 7As shown in the results, the TSLP level in the blank group was 1.40±0.14pg / mg protein, the model group was 2.80±0.36pg / mg protein, the phytochemical group was 2.10±0.32pg / mg protein, the mixed bacteria group was 2.30±0.37pg / mg protein, the old formula group was 1.89±0.22pg / mg protein, and the new formula group was 1.57±0.18pg / mg protein. Compared with 1.40±0.14pg / mg protein in the blank group, the TSLP level in the model group increased significantly to 2.80±0.36pg / mg protein (P<0.001). Compared with the model group, phytochemical, mixed bacteria and formula intervention could significantly reduce the TSLP level in the serum of mice, and the new formula group had the best effect in reducing the TSLP level in the serum (P<0.001).

[0076] Example 6 Effect of formula intervention on mast cell infiltration in the back skin of mice with atopic dermatitis

[0077] The specific steps are as follows: After the animal experiment, 1%-1.5% isoflurane inhalation anesthesia was used to dissect the skin tissue of the mouse modeling site. The skin tissue was fixed with polyformaldehyde, embedded in paraffin, and then cut into 5μm thick slices. After baking, a series of alcohol dehydration, and then stained with mast cell staining solution, differentiated, and transparently sealed to make pathological sections. Three different fields of view were selected under an optical microscope to count the number of mast cells. The results are shown in Figure 8 .

[0078] The results show that: Figure 8 As shown, the blank group unit area (mm 2 ) The number of mast cells in the model group was 23.13±3.66, 70.26±12.51 in the model group, 42.98±6.14 in the plant group, 58.33±16.07 in the mixed bacteria group, 37.61±8.40 in the old formula group, and 31.39±4.33 in the new formula group. Compared with the blank group, the model group mice showed significant pathological symptoms of mast cell inflammatory infiltration in the back lesions, and the number of mast cells increased significantly to 70.26±12.51 (P<0.001). Compared with the model group, the inflammatory infiltration of mast cells in the skin of mice in the plant group and the old formula group was significantly reduced (p<0.01), and the mixed bacteria group also alleviated skin inflammation to a certain extent, but there was no statistical significance. The above results show that the new formula intervention significantly inhibits the infiltration of inflammatory cells in the skin lesions, and the effect is better than that of plants, mixed bacteria and old formula.

[0079] In summary, the probiotic provided by the present invention has a good effect in improving atopic dermatitis and alleviating related pathological symptoms.

[0080] Although the specific implementation modes of the present invention are described above, those skilled in the art should understand that the specific implementation modes described are only illustrative and are not intended to limit the scope of the present invention. Equivalent modifications and changes made by those skilled in the art in accordance with the inventive concept of the present invention should be included in the scope of protection of the claims of the present invention.

Claims

1. A probiotic agent capable of relieving allergies, characterized in that: The allergy-relieving probiotics include Lactobacillus casei CCFM1073 strain with a preservation number of GDMCC No: 60736, Lactobacillus gasseri CCFM1182 strain with a preservation number of GDMCC No: 61608, Lactobacillus plantarum CCFM1050 strain with a preservation number of GDMCC No: 60604, Bifidobacterium longum CCFM1029 strain with a preservation number of GDMCC No: 60461, Bifidobacterium animalis CCFM1155 strain with a preservation number of GDMCC No: 61495, Lactobacillus reuteri strain with a preservation number of GDMCC No: 61151, and Lactobacillus plantarum CCFM1050 strain with a preservation number of GDMCC No: 60604. The ratio of the number of viable bacteria of the CCFM1145 strain, the CCFM1073 strain, the CCFM1182 strain, the CCFM1029 strain, the CCFM1050 strain and the CCFM1155 strain is 1:(0.1-10):(0.05-10):(0.1-10):(0.1-10).

2. The probiotic for allergy relief according to claim 1, characterized in that: In the probiotics, the total number of viable bacteria is not less than 1×10 9 CFU / g.

3. The probiotic for allergy relief according to claim 1, characterized in that: The probiotics also include prebiotics, which contain one or more of xylooligosaccharides, fructooligosaccharides, galacto-oligosaccharides or inulin.

4. The probiotic for allergy relief according to claim 3, characterized in that: The concentration of the prebiotics is not less than 0.66 g / g.

5. The probiotic for allergy relief according to claim 1, characterized in that: The probiotics also include food raw materials, and / or food or medically acceptable auxiliary materials or additives.

6. The probiotic for allergy relief according to claim 1, characterized in that: The dosage form of the probiotics includes freeze-dried powder, capsules, tablets or granules.

7. Use of the probiotic for allergy relief according to any one of claims 1 to 6 in the preparation of a drug for allergy relief or treatment.

8. Use of the probiotic for allergy relief according to any one of claims 1 to 6 in the preparation of a product having at least one of the following functions: (1) Can significantly improve the skin pathological symptoms of mice; (2) It can significantly improve the swelling of mice's ears; (3) It can significantly reduce the total IgE level in mouse serum; (4) Can significantly regulate the levels of inflammatory factors in mice; (5) It can significantly alleviate mast cell infiltration in the back skin of mice.

Citation Information

Patent Citations

  • Bifidobacterium longum capable of relieving atopic dermatitis and application thereof

    CN109652349A

  • Lactobacillus plantarum capable of improving sleep and application thereof

    CN110106122A

  • Lactobacillus casei capable of adjusting balance of allergic asthma Th2 / Th1 and application of lactobacillus casei

    CN110643541A

  • Lactobacillus reuteri capable of intervening in metabolic syndrome and application

    CN112322527A

  • Bifidobacterium animalis with function of relieving oxidative damage of HaCaT cells

    CN113088473A

Cited By

  • Probiotic composition with functions of resisting allergy and enhancing immunity

    CN122303074A

  • A probiotic composition with anti-allergy and immune-boosting functions

    CN122303074B